Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial
When I began caring for people with HIV in the early 1980s, the disease was usually a death sentence. We had no drugs to fight the virus, and most of our patients died within months to a year. It wasn’t until 1996 that a combination of drugs known as the “anti-HIV cocktail” was able to suppress the virus and improve patients’ health. So it was noteworthy when at a major AIDS meeting in Seattle this month, researchers made the announcement: For the second time in history, a man had been cured of HIV.
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases. CROI 2019 will be held from March 4 to March 7, 2019, at the Washington State Convention Center in Seattle, Washington.
The Southern African HIV Clinicians Society’s biannual conference, held in Johannesburg, South Africa, from 24-27 October 2018, focused on clinical content for HIV and TB health care workers in the region and featured a wide range of topics, from new antiretroviral drugs, AIDS-related complications, and opportunistic infections, to promoting adherence and ethical issues.
This fact sheet provides detailed information for patients about the non-nucleoside reverse transcriptase inhibitor (NNRTI) Doravirine (Pifeltro).
The HIV New Product Introduction Toolkit provides Ministries of Health (MoHs) and implementing partners with the tools necessary to evaluate the adoption and introduction of new products in their local context. The toolkit includes a wide-range of information, tools, and resources spanning the entire chain of product introduction including product adoption, forecasting, procurement, facility phase-in, and supply planning and monitoring, ensuring that products reach those in need of them.
HIV New Product Introduction Guide: A framework for supporting new product introduction in national health systems
Over the past two decades, the landscape of medications used to treat HIV has evolved rapidly. Treatment options have improved dramatically with the development and availability of more efficacious, safer, and more tolerable antiretrovirals (ARVs). These options allow national treatment programs to better serve the needs of their patients, support significant treatment scale-up, reduce costs, and achieve public health goals. Use of the most optimal regimens and products offers many benefits to national HIV programs and people living with HIV (PLHIV).
The Southern African HIV Clinicians Society’s biannual conference focuses on clinical content for HIV and TB health care workers. The 2018 conference programme has been carefully designed to benefit all health care practitioners, with topics ranging from new antiretroviral drugs, AIDS-related complications, opportunistic infections, promoting adherence and ethical issues.
HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study
HIV drug resistance (HIVDR) poses a threat to future antiretroviral therapy success. Monitoring HIVDR patterns is of particular importance in populations such as sex workers (SWs), where documented HIV prevalence is between 34-89%, and in countries with limited therapeutic options. Currently in South Africa, there is a dearth in evidence and no ongoing surveillance of HIVDR amongst sex work populations. This study aims to describe the prevalence of HIVDR amongst a sample of female sex workers (FSWs) from Soweto, South Africa.